Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1496
Shown on this page
12
Current sort
Recently updated
Campus scope
Duke University Medical Center, Durham, NC
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Duke University Medical Center, Durham, NC. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 481–492 of 1,496 matching trials with a site at Duke University Medical Center, Durham, NC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions
CTX310
Drug
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796
Status at this site: Recruiting
View directory record Official record
Conditions
Neoplasms
Interventions
Gene-modified (GM) T cell therapy
Genetic
Lead sponsor
Celgene
Industry
Eligibility
Not listed
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
103
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat A, Etavopivat B, Etavopivat C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

NCT07746271
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension in Pregnancy, Obstetrical Complications
Interventions
Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
14 Years to 56 Years · Female only
Enrollment
4,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235
Status at this site: Recruiting
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
Site status not listed — check the official record
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Identifying Patterns in the Breath of Individuals With Breast Cancer

NCT06512350
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Breathe BioMedical Inc
Industry
Eligibility
40 Years to 74 Years · Female only
Enrollment
5,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care

NCT07738874
Status at this site: Recruiting
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Ultra-widefield Optical Coherence Tomography (UWF-OCT), Wide-field ophthalmic imaging system
Device
Lead sponsor
Duke University
Other
Eligibility
0 Days to 9 Months
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

NCT03911505
Site status not listed — check the official record
View directory record Official record
Conditions
Pompe Disease (Late-onset)
Interventions
Cipaglucosidase Alfa, Miglustat
Biological · Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
0 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

NCT06816927
Status at this site: Recruiting
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Nivolumab, Relatlimab, TMZ, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 2:09 PM EDT

About this Duke University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Duke University at any site, browse by condition, or browse by U.S. city.